Artelo Biosciences (NASDAQ:ARTL) Posts Earnings Results, Beats Estimates By $3.83 EPS

Artelo Biosciences (NASDAQ:ARTL) announced its quarterly earnings results on Thursday. The company reported ($3.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.02) by $3.83, FiscalAI reports.

Artelo Biosciences Stock Down 2.1%

Shares of ARTL traded down $0.05 on Thursday, reaching $2.15. The stock had a trading volume of 28,000 shares, compared to its average volume of 288,320. Artelo Biosciences has a twelve month low of $1.91 and a twelve month high of $179.19. The firm has a market capitalization of $1.18 million, a PE ratio of -0.01 and a beta of 0.01. The firm has a 50-day moving average of $3.64 and a 200 day moving average of $20.18.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, September 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce”.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a biological signaling network involved in areas such as pain, appetite, inflammation and cancer. The company’s programs are designed to address unmet medical needs in oncology and other therapeutic areas. Artelo’s development pipeline has included ART27.13, a peripherally restricted cannabinoid receptor type 1 agonist being investigated for cancer-related anorexia and cachexia.